{"id":240521,"date":"2026-07-09T03:28:07","date_gmt":"2026-07-09T08:28:07","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/07\/new-improved-method-to-find-and-isolate-the-strongest-cancer-fighting-immune-cells"},"modified":"2026-07-09T03:28:07","modified_gmt":"2026-07-09T08:28:07","slug":"new-improved-method-to-find-and-isolate-the-strongest-cancer-fighting-immune-cells","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/07\/new-improved-method-to-find-and-isolate-the-strongest-cancer-fighting-immune-cells","title":{"rendered":"New, improved method to find and isolate the strongest cancer-fighting immune cells"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-improved-method-to-find-and-isolate-the-strongest-cancer-fighting-immune-cells.jpg\"><\/a><\/p>\n<p>A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells. This approach addresses a major bottleneck in immunotherapy development and could accelerate the creation of personalized treatments.<\/p>\n<p>The platform, called ATTACH (Assessment of T cells Tethered to Antigen Class I Histocompatibility), identifies the strongest interactions between T cells and cancer-specific proteins, isolating only the most effective, tumor-reactive T cells for further study and therapeutic use.<\/p>\n<p>The study, <a href=\"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014960\" target=\"_blank\">published<\/a> today in the <i>Journal for ImmunoTherapy of Cancer<\/i>, was led by Alexandre Reuben, Ph.D., assistant professor of Thoracic\/Head and Neck Medical Oncology, and Amanda Montoya, senior research assistant in the Reuben lab.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells. This approach addresses a major bottleneck in immunotherapy development and [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-240521","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/240521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=240521"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/240521\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=240521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=240521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=240521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}